1
Walden NURS 6630 Psychopharmacology Final Exam
2026/2027 Actual Exam | 50 Questions & Verified
Correct Answers with Detailed Rationales | Newest
Version | Pass Guaranteed - A+ Graded
Section 1: Neurobiology and Receptor Pharmacology
Q1: A patient is started on fluoxetine (Prozac) for major depressive disorder. The PMHNP
understands that the therapeutic effect of SSRIs is primarily due to:
A. Blocking dopamine D2 receptors
B. Inhibiting the reuptake of serotonin at the presynaptic neuron [CORRECT]
C. Blocking acetylcholinesterase
D. Enhancing GABA activity
Correct Answer: B
Rationale: SSRIs work by selectively inhibiting the reuptake of serotonin at the presynaptic
neuron, increasing serotonin availability in the synaptic cleft. Option A describes antipsychotics.
Option C describes Alzheimer's medications. Option D describes benzodiazepines and other
GABAergic drugs.
Q2: The PMHNP is explaining the "dopamine hypothesis" of schizophrenia to a student. The
PMHNP explains that positive symptoms (hallucinations, delusions) are thought to be caused by:
A. Dopamine deficiency in the mesocortical pathway.
B. Dopamine hyperactivity in the mesolimbic pathway. [CORRECT]
C. Dopamine hyperactivity in the nigrostriatal pathway.
D. Serotonin hyperactivity in the raphe nuclei.
Correct Answer: B
Rationale: The mesolimbic pathway is associated with positive symptoms when dopamine is
overactive. The mesocortical pathway (A) is associated with negative/cognitive symptoms due to
,2
dopamine deficiency. The nigrostriatal pathway (C) regulates movement; blockade here causes
EPS.
Q3: A patient is prescribed a medication that acts as a partial agonist at the dopamine D2
receptor. The PMHNP explains that this medication will:
A. Fully stimulate the receptor regardless of dopamine levels.
B. Block the receptor completely, preventing any dopamine binding.
C. Stimulate the receptor partially when dopamine is low and block it when dopamine is high.
[CORRECT]
D. Only block the reuptake of dopamine.
Correct Answer: C
Rationale: Partial agonists (like aripiprazole) act as a stabilizer. They provide enough stimulation
to prevent deficit (low dopamine) but not enough to cause excess (high dopamine), effectively
acting as an agonist in deficit areas and an antagonist in excess areas.
Q4: Which cytochrome P450 enzyme is responsible for the metabolism of most SSRIs (e.g.,
fluoxetine, paroxetine) and is a common site for drug-drug interactions?
A. CYP3A4
B. CYP2D6 [CORRECT]
C. CYP1A2
D. CYP2C19
Correct Answer: B
Rationale: CYP2D6 is a major enzyme for metabolizing many antidepressants and
antipsychotics. Fluoxetine and paroxetine are potent inhibitors of CYP2D6, which can lead to
increased levels of other drugs metabolized by this pathway.
Q5: The therapeutic effect of benzodiazepines is mediated by:
A. Opening chloride channels independent of GABA.
, 3
B. Binding to the GABA-A receptor and increasing the frequency of chloride channel opening.
[CORRECT]
C. Binding to the GABA-B receptor and increasing potassium conductance.
D. Inhibiting the breakdown of GABA.
Correct Answer: B
Rationale: Benzodiazepines bind to an allosteric site on the GABA-A receptor, facilitating the
binding of GABA. This increases the frequency of chloride channel opening, leading to
hyperpolarization of the neuron and a calming effect. Barbiturates increase the duration of
opening.
Q6: A patient is a "poor metabolizer" of CYP2D6 substrates. How should the PMHNP adjust the
dose of a tricyclic antidepressant (TCA) like nortriptyline?
A. Increase the standard dose.
B. Decrease the standard dose. [CORRECT]
C. No adjustment is needed; metabolizer status does not affect lipophilic drugs.
D. Switch to a drug metabolized by CYP2D6.
Correct Answer: B
Rationale: Poor metabolizers have reduced enzyme activity, leading to slower drug breakdown.
If a standard dose is given, the drug accumulates, increasing the risk of toxicity. Therefore, doses
should typically be lowered.
Q7: "Tardive dyskinesia" is a serious adverse effect associated with long-term blockade of
dopamine D2 receptors in which pathway?
A. Mesolimbic
B. Mesocortical
C. Nigrostriatal [CORRECT]
D. Tuberoinfundibular
Walden NURS 6630 Psychopharmacology Final Exam
2026/2027 Actual Exam | 50 Questions & Verified
Correct Answers with Detailed Rationales | Newest
Version | Pass Guaranteed - A+ Graded
Section 1: Neurobiology and Receptor Pharmacology
Q1: A patient is started on fluoxetine (Prozac) for major depressive disorder. The PMHNP
understands that the therapeutic effect of SSRIs is primarily due to:
A. Blocking dopamine D2 receptors
B. Inhibiting the reuptake of serotonin at the presynaptic neuron [CORRECT]
C. Blocking acetylcholinesterase
D. Enhancing GABA activity
Correct Answer: B
Rationale: SSRIs work by selectively inhibiting the reuptake of serotonin at the presynaptic
neuron, increasing serotonin availability in the synaptic cleft. Option A describes antipsychotics.
Option C describes Alzheimer's medications. Option D describes benzodiazepines and other
GABAergic drugs.
Q2: The PMHNP is explaining the "dopamine hypothesis" of schizophrenia to a student. The
PMHNP explains that positive symptoms (hallucinations, delusions) are thought to be caused by:
A. Dopamine deficiency in the mesocortical pathway.
B. Dopamine hyperactivity in the mesolimbic pathway. [CORRECT]
C. Dopamine hyperactivity in the nigrostriatal pathway.
D. Serotonin hyperactivity in the raphe nuclei.
Correct Answer: B
Rationale: The mesolimbic pathway is associated with positive symptoms when dopamine is
overactive. The mesocortical pathway (A) is associated with negative/cognitive symptoms due to
,2
dopamine deficiency. The nigrostriatal pathway (C) regulates movement; blockade here causes
EPS.
Q3: A patient is prescribed a medication that acts as a partial agonist at the dopamine D2
receptor. The PMHNP explains that this medication will:
A. Fully stimulate the receptor regardless of dopamine levels.
B. Block the receptor completely, preventing any dopamine binding.
C. Stimulate the receptor partially when dopamine is low and block it when dopamine is high.
[CORRECT]
D. Only block the reuptake of dopamine.
Correct Answer: C
Rationale: Partial agonists (like aripiprazole) act as a stabilizer. They provide enough stimulation
to prevent deficit (low dopamine) but not enough to cause excess (high dopamine), effectively
acting as an agonist in deficit areas and an antagonist in excess areas.
Q4: Which cytochrome P450 enzyme is responsible for the metabolism of most SSRIs (e.g.,
fluoxetine, paroxetine) and is a common site for drug-drug interactions?
A. CYP3A4
B. CYP2D6 [CORRECT]
C. CYP1A2
D. CYP2C19
Correct Answer: B
Rationale: CYP2D6 is a major enzyme for metabolizing many antidepressants and
antipsychotics. Fluoxetine and paroxetine are potent inhibitors of CYP2D6, which can lead to
increased levels of other drugs metabolized by this pathway.
Q5: The therapeutic effect of benzodiazepines is mediated by:
A. Opening chloride channels independent of GABA.
, 3
B. Binding to the GABA-A receptor and increasing the frequency of chloride channel opening.
[CORRECT]
C. Binding to the GABA-B receptor and increasing potassium conductance.
D. Inhibiting the breakdown of GABA.
Correct Answer: B
Rationale: Benzodiazepines bind to an allosteric site on the GABA-A receptor, facilitating the
binding of GABA. This increases the frequency of chloride channel opening, leading to
hyperpolarization of the neuron and a calming effect. Barbiturates increase the duration of
opening.
Q6: A patient is a "poor metabolizer" of CYP2D6 substrates. How should the PMHNP adjust the
dose of a tricyclic antidepressant (TCA) like nortriptyline?
A. Increase the standard dose.
B. Decrease the standard dose. [CORRECT]
C. No adjustment is needed; metabolizer status does not affect lipophilic drugs.
D. Switch to a drug metabolized by CYP2D6.
Correct Answer: B
Rationale: Poor metabolizers have reduced enzyme activity, leading to slower drug breakdown.
If a standard dose is given, the drug accumulates, increasing the risk of toxicity. Therefore, doses
should typically be lowered.
Q7: "Tardive dyskinesia" is a serious adverse effect associated with long-term blockade of
dopamine D2 receptors in which pathway?
A. Mesolimbic
B. Mesocortical
C. Nigrostriatal [CORRECT]
D. Tuberoinfundibular
